Purpose Intracranial administration of lipopolysaccharide (LPS) is known to elicit a rapid innate immune response, activate glial cells in the brain, and induce depression-like behavior. However, no study has focused on the changes in glial cells induced by intraperitoneal injection of LPS in vivo. Methods Ten adult male Fischer F344 rats underwent [ 
Introduction
Major depressive disorder (MDD) is a mood disorder characterized by a persistent feeling of sadness or a lack of interest in external stimuli. Besides the well-established role of monoaminergic system dysfunction in the pathophysiology of the disorder, growing evidence suggests its strong link with inflammatory phenomena [1] . This link is supported by the fact that administration of cytokines can induce many features of depression that are common to humans and in animals [2] . Furthermore, administration of cytokine inducer causes depressive symptoms in humans [3] and depression-like behavior in rodents [4] [5] [6] [7] [8] [9] [10] . In line with these findings, we have reported that cerebrospinal fluid interleukin-6 levels are higher in patients with depressive disorder than in controls, suggesting the presence of neuroinflammation in the illness [11] . Lipopolysaccharides (LPS), also known as endotoxins, are found in the outer membrane of gram-negative bacteria, and elicit strong immune responses. Peripheral inflammation induced by LPS causes depression-like behaviors in rats [6] [7] [8] [9] [10] . Further, intraperitoneal injection of LPS activates microglial cells in rats [12, 13] and mice [12, 14, 15] .
Positron emission tomography (PET) using radiolabeled ligands selective for the 18-kDa translocator protein (TSPO) is one of the most widely used in vivo techniques for the assessment of inflammatory abnormalities, specifically those associated with the activation of microglia. Radiolabeled ligands with affinity for TSPO, such as the 11 C-labeled
, have been used to detect putative neuroinflammation and associated microglial activation. Many PET studies in humans have evaluated the relationships between TSPO and mental disorders, such as MDD [16] [17] [18] , bipolar disorder [19] and schizophrenia [20] . In animals, some PET studies have evaluated the change in microglia cells induced by injection of LPS in the brain [21, 22] . However, these changes in glial cells are the effect of direct neural disturbance by LPS, and are not caused by peripheral administration of LPS. In this study, we examined whether neuroinflammation would be induced by intraperitoneal injection of LPS in vivo using [ 
Materials and Methods

Animals
Ten adult male Fischer F344 rats weighing 164 to 216 g at the start of the experiment were purchased from Charles River Laboratories Japan, Inc. They were housed two per cage with free access to food and water. The housing room was maintained at a constant temperature of 22 ± 2°C with a 12/12-h modified dark/light cycle (lights off at 8:00 a.m.).
Drug Administration and Scan Schedule
The baseline accumulation of [ 11 C]PK11195 was estimated by PET. After at least 2 days, LPS (Sigma, St Louis, MO; serotype 055:B5) was injected intraperitoneally at a dose of 2.0 mg/kg that has been shown to induce changes indicative of depression in human subjects [10] . Then, to estimate LPSinduced changes in glial cells in terms of accumulation of [ 11 C]PK11195, a second PET scan was performed 2 days after LPS administration.
PET Study
]PK11195 was synthesized as described previously [23] . Mean specific activity was 5.3 ± 1.7 GBq/μmol.
Animal PET images were acquired using a Clairvivo PET scanner (Shimadzu Corp., Kyoto, Japan) [24] . This scanner includes depth of interaction detector modules with an axial field of view (FOV) of 151 mm yielding 213 contiguous slices, a transaxial FOV of 100 mm (matrix 128 × 128), and a transaxial spatial resolution of 1.5 mm in the center. The rats were initially anesthetized with 3% isoflurane vaporized in oxygen, and were placed in the PET gantry with their brain positioned in the center of the FOV. Anesthesia was maintained at 2% during PET scanning and their body temperature was maintained using a heating blanket. [ 11 C]PK11195 (18.1 ± 2.3 MBq) was injected as a bolus via a tail vein. Dynamic data were acquired over 60 min after injection, and the whole dynamic acquisition was divided into 6 frames at 10 s, 6 at 30 s, 11 at 60 s, and 15 at 180 s. Dynamic images were reconstructed using an iterative three-dimensional dynamic row-action maximum likelihood algorithm [25] . After the PET scan, MRI was performed using a MRS 3017 3-T scanner (MR Solutions, Guildford, UK) for each rat. No abnormal MRI findings were detected in the brain of any rat.
PET Data Analysis
First, each PET summation image of all frames was spatially normalized to one individual PET summation image. Then a template of [ 11 C]PK11195 accumulation was created from these spatially normalized PET summation images. Next, to evaluate the change in [ 
Statistical Analysis
Statistical analysis of smoothed SUV images was performed using Statistical Parametric Mapping 8 software (SPM8; Wellcome Department of Imaging Neuroscience, L o n d o n , U K ) r u n n i n g w i t h M AT L A B R 2 0 1 3 a (MathWorks, Natick, MA). Paired t tests were performed to evaluate the regional SUV change in [
11 C]PK11195 accumulation between before and after intraperitoneal injection of LPS. Dynamic PET images and PET summation images showed accumulation of [ 11 C]PK11195 outside the skull. The intracranial space of normalized CT images was manually traced, and the space was used to mask the results of the paired t test above. Only differences that achieved a threshold level of p < 0.05 (corrected for false-discovery rate, FDR) and a cluster level of p < 0.05 (uncorrected) were deemed significant.
Results
After LPS injection, at the time of the second PET scan, there was a significant reduction in body weight compared with that at the time of the first scan (200.0 ± 14.8 g to 183.5 ± 8.0 g, t = 5.8, p < 0.001, paired t test). After LPS injection, a cluster showed a significant reduction in [ 11 C]PK11195 SUV (cluster size 39, Z score 3.25; p = 0.033, FDR-corrected). This cluster included the bilateral striata and bilateral frontal regions, especially the somatosensory areas (Fig. 1 ). There were no other changes in any region within the skull after LPS injection.
Discussion
We evaluated the neuroinflammation induced by intraperitoneal injection of LPS in vivo using [ 11 C]PK11195 PET, and found a significant reduction in [ 11 C]PK11195 accumulation after LPS injection in the frontal regions, especially the somatosensory area, compared with baseline. To our knowledge, this is the first study that has evaluated the changes in glial cells after intraperitoneal injection of LPS using [ 11 C]PK11195 PET. We found changes in TSPO notably in the somatosensory area. In the rat, region S1 contains an area representing general visceral information [27] , and previous studies in the rat have shown that intravenous administration of LPS induces changes in S1 activity [28] and chemokine expression that play an important role in the recruitment and regulation of leukocyte traffic during bacterial infection in the brain [29] . These findings are congruent with our results. We also found no significant changes in SUV in the cerebellum.
In [ 11 C]PK11195 PET studies in humans focusing on neurodegenerative disorders, such as Alzheimer's disease, the cerebellum is sometimes regarded as a reference area in which nonspecific binding and free tracer coexist [30] [31] [32] . This is consistent with our result. In animal studies, however, intraperitoneal injection of LPS causes diffuse neuroinflammation in the brain [28, 29] . In single photon emission computed tomography (SPECT) studies, both 99m Tc-HMPAO and 99m
Tc-ECD have been used in the calculation of regional cerebral blood flow. However, their perfusion patterns are different, and the pharmacodynamics of the radioligand often affects the images [33] . From this aspect, the regional differences in the changes in SUV found in this study may in part have resulted not from the TSPO accumulation but from the perfusion pattern of PK11195.
Several PET studies have shown significant increases in TSPO in neurodegenerative diseases, such as multiple sclerosis [32] and Alzheimer's disease [30] . With regard to TSPO in MDD, however, it is unclear whether neuroinflammation occurs. Although some PET studies have shown an increase in TSPO [17, 18] , the opposite result (a decrease) has also been reported [16] . Similarly, mixed results have been reported in post-mortem studies in MDD [34, 35] . Microglial activation leads to neuroinflammatory responses that exert both beneficial and detrimental effects through host defense and tissue repair processes [36, 37] . During neuroinflammatory periods, activated microglia are able to clear debris and invading pathogens, and produce neurotrophic factors that modulate the microenvironment [38] . When sensing ATP leaks from an injury site, microglia transform into a more motile state and migrate to the damaged site [39] which causes neuroinflammation and subsequent neurodegeneration. Further, TSPO is The numbers indicate the ROIs: 1 olfactory bulb, 2 neocortex, 3 striatum, 4 hippocampal formation, 5 thalamus, 6 corpus callosum and associated subcortical white matter involved in the regulation of several major stress systems, i.e., the hypothalamic-pituitary-adrenal axis, the sympathetic nervous system, the renin-angiotensin axis, and the neuroendocrine-immune axis [40] . Our results may have been affected not only by LPS-induced neuroinflammation but also by the stress response from depression.
This study had some limitations. First, we did not find behavioral changes in our animals. However, previous studies have found that male rats show depressive behaviors [6, 9, 10] and glial activation [12, 13] 1 or 2 days after LPS administration. Our results would reflect the LPS-induced depression-like changes. Second, in accordance with our results, previous studies have also shown that LPS administration induces weight loss in rats [6, 9] . Weight loss would then have led to an increase in the [ 11 C]PK11195 injection dose per weight of rat. However, our results showed a significant reduction in SUV after LPS injection. Therefore, the influence of weight loss was thought to be negligible. Third, we used SUV to represent [ ]PK11195 with a low potential for binding to TSPO could not bind to the target because of competition from endogenous substrates that also bind to TSPO. Future studies with second-generation TSPO PET tracers using kinetic modeling may need to be conducted to calculate TSPO concentrations.
Conclusions
We evaluated activity changes in glial cells induced by intraperitoneal injection of LPS using [ 11 C]PK11195 PET in vivo. Contrary to our expectation, we found a reduction in SUV after LPS injection. It is well known that intraperitoneal injection of LPS induces depression-like behavior, and further studies with [ 11 C]PK11195 PET would clarify the relationships between neuroinflammation and depression using the same methodology.
